Peake to provide guidance and direction regarding military needs, clinical uses and funding sources
ROCKVILLE, Md., June 30 /PRNewswire/ -- Cellphire, Inc., a biotechnology company located in Rockville, Md., announced today that former Secretary of the Department of Veterans Affairs, James Peake, MD, has joined its board of directors.
"I am excited about the potential of Thrombosomes(R) to save lives on the battlefield and in emergency rooms throughout the US. I am eager to contribute to the effort to conduct appropriate clinical trials to evaluate and ultimately field this product," said Dr. Peake.
Cellphire is committed to developing a freeze-dried platelet product, Thrombosomes(R), which could potentially be effective in stopping uncontrollable bleeding on the battlefield or in trauma. Platelets can only be stored for 5 days and cannot be provided to combat zones, although in-the-field harvesting is being performed. Cellphire's product is expected to have a 12 month shelf life and be immediately available for infusion after adding sterile water.
"We are excited about the addition of Dr. Peake to the Cellphire Board," said Cellphire President Mike Fitzpatrick. "With his incomparable experience and tireless commitment to providing the best possible care for the active duty uniformed services and veterans, we feel sure his contributions will help us achieve our goal."
Dr. Peake is a retired U.S. Army Lieutenant General; he was selected as the U.S. Army Surgeon General. After retirement from the Army he served as the Executive Vice President and Chief Operating Officer of Project Hope and most recently as the Secretary of the U.S. Department of Veterans Affairs. A native of St. Louis and graduate of the
Cellphire, Inc., a biotechnology company, is focused on developing stabilized cellular materials for advanced technologies in the therapeutic and diagnostic markets. Current efforts and product development are aimed toward stabilized platelets for advanced wound care, transfusion, and reagent products for clinical and research diagnostics.
|SOURCE Cellphire, Inc.|
Copyright©2009 PR Newswire.
All rights reserved